Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.33 |
| ▸ | CASP1 | P29466 | 4/20 | 0.32 |
| ▸ | CASP3 | P42574 | 4/20 | 0.32 |
| ▸ | CASP7 | P55210 | 4/20 | 0.32 |
| ▸ | CASP6 | P55212 | 4/20 | 0.32 |
| ▸ | CASP8 | Q14790 | 4/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | CCKBR | P32239 | 1/20 | 0.31 |
| ▸ | REN | P00797 | 2/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2800524 | 0.85 | OPRM1 (0.33) | TRPM8CASP1CASP3CASP7CASP6 | |
| SCHEMBL2802690 | 0.85 | TRPM8 (0.32) | TRPM8CASP1CASP3CASP7CASP6 | |
| SCHEMBL2799392 | 0.84 | KMT2A (0.31) | CASP1CASP3CASP7CASP6CASP8 | |
| SCHEMBL2800052 | 0.83 | CASP1 (0.30) | CASP1CASP3CASP7CASP6CASP8 | |
| SCHEMBL2799393 | 0.82 | TRPM8 (0.34) | TRPM8CASP1CASP3CASP7CASP6 | |
| SCHEMBL5350670 | 0.82 | TRPM8 (0.32) | TRPM8CASP1CASP3CASP7CASP6 | |
| SCHEMBL2800010 | 0.81 | TNKS2 (0.32) | TRPM8CASP1CASP3CASP7CASP6 | |
| SCHEMBL2800012 | 0.79 | TRPM8 (0.33) | TRPM8CASP1CASP3CASP7CASP6 | |
| SCHEMBL2799206 | 0.79 | L3MBTL1 (0.37) | CASP1CASP3CASP7CASP6CASP8 | |
| SCHEMBL949530 | 0.74 | CASP3 (0.38) | CASP1CASP3CASP7CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
| US-7772366-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-10 | — | — | US | disclosed |
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-7288624-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-30 | — | — | US | disclosed |
| US-20020099042-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED | 2002-07-25 | — | — | US | disclosed |
| US-6420522-B1 | ENZYME INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2002-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1R1 | TRPM8 3450/4885CASP1 5/4885CASP3 542/4885 |
| US-20020099042-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1RN | TRPM8 3541/4885CASP1 6/4885CASP3 555/4885 |
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1B, IL1A, IL1R1 | TRPM8 3450/4885CASP1 5/4885CASP3 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.